Mobile

Randomized, placebo controlled, double blind, multi-center phase II proof-of-concept study to assess the efficacy of AIN457 in patients with moderate to severe ankylosing spondylitis

Update Il y a 5 ans
Reference: EUCTR2008-002631-33

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

Part 1: To evaluate the efficacy of AIN457 at 6 weeks based on the proportion of patients achieving an ASAS20 response Part 2: To evaluate the efficacy of lower doses of AIN457 at 6 weeks based on the change in BASDAI score

Inclusion criteria

  • Ankylosing spondylitis (AS), which belongs to seronegative spondyloarthropathies (SpA)

Links